Prenoxad® Solution for Injection (naloxone hydrochloride)

Each prefilled syringe contains naloxone hydrochloride 1 mg/mL to 2 mL. It is a sterile, clear and colourless liquid with a pH of 3.0-4.0. Excipients include sodium chloride, hydrochloric acid (for pH adjustment) and water for injections.

Indication:
Prenoxad Solution for Injection is intended for the complete or partial reversal of respiratory depression induced by natural and synthetic opioids. It may also be used for the diagnosis of suspected acute opioid overdose. Please note that although not registered in Australia, Prenoxad Solution for Injection is approved for general marketing in the United Kingdom. The Therapeutic Goods Administration has granted Phebra temporary approval to supply this product under Section 19A of the Therapeutic Goods Act 1989. The Product Information and the Consumer Medicine Information are versions approved for use in the UK, and therefore contact information for adverse drug reactions, medical enquiries and emergency numbers are not applicable. Any enquiries or adverse drug event reporting for Prenoxad Solution for Injection should be directed to Phebra (the Australian supplier) on 1800 720 020. Should medical assistance be required, call 000. Refer to Product Information for full indication.